

Oxford Immunotec submits EUA for T-SPOT.COVID test

March 17, 2021—[Oxford Immunotec](#) has released the T-SPOT.COVID test, a CE-marked, ELISpot-based test intended for qualitative detection of T-cell immune response to SARS-CoV-2 in human whole blood.

In a clinical study using samples collected in the U.S., the T-SPOT.COVID test was proven to detect a SARS-CoV-2 cell-mediated immune response in PCR-positive individuals, even with negative serology test results. The test therefore complements results obtained by antibody serology, the company says, to give a more comprehensive view of a person's adaptive immune response to SARS-CoV-2 infection.

"T cells and antibodies are two arms of the adaptive immune response. The detection and measurement of each can provide different insights about disease activity and an individual's personal immunity," Phill Keefe, senior VP, product design, development, and delivery, Oxford Immunotec, said in a press statement.

The company has filed an EUA for the test.